Genomic and Transcriptomic Characteristics of Tumors of Patients with Metastatic Clear Cell Renal Cell Carcinoma Clinically Benefiting from First-Line Treatment with Ipilimumab Plus Nivolumab

Background: Ipilimumab plus nivolumab is approved as a first-line treatment for intermediate or poor risk metastatic renal cell carcinoma (mRCC). However, ∼35% of patients progress within six months on ipilimumab plus nivolumab, and no validated genomic biomarkers predict the benefit. In this study,...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Nishita Tripathi, Luis Meza, Nicolas Sayegh, Ameish Govindarajan, Sara A. Byron, Jiaming Zhang, Beverly Chigarira, Yeonjung Jo, Zeynep B. Zengin, Haoran Li, Georges Gebrael, Arpita Desai, Neeraj Agarwal, Umang Swami, Benjamin L. Maughan, Sumanta K. Pal
Format:	Artigo
Sprog:	Inglês
Udgivet:	SAGE Publishing 2023-12-01
Serier:	Kidney Cancer
Online adgang:	https://doi.org/10.3233/KCA-230011
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!